These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11475271)

  • 1. The importance of rapid insulin secretion: revisited.
    Grodsky GM
    Diabetes Technol Ther; 1999; 1(3):259-60. PubMed ID: 11475271
    [No Abstract]   [Full Text] [Related]  

  • 2. [Repaglinide (NN-623)].
    Kaku K
    Nihon Rinsho; 1997 Nov; 55 Suppl():180-5. PubMed ID: 9434464
    [No Abstract]   [Full Text] [Related]  

  • 3. [Prandial glucose regulator for type 2 diabetic patients. Beta cells produce insulin according to need].
    MMW Fortschr Med; 1999 Sep; 141(36):61. PubMed ID: 10904606
    [No Abstract]   [Full Text] [Related]  

  • 4. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
    Kikuchi M
    Diabet Med; 1996 Sep; 13(9 Suppl 6):S151-5. PubMed ID: 8894500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repaglinide dose response? A clinician's viewpoint.
    Schade DS
    Diabetes Technol Ther; 1999; 1(3):257-8. PubMed ID: 11475270
    [No Abstract]   [Full Text] [Related]  

  • 6. [Type 2 diabetes mellitus pathogenesis: new therapeutic managements?].
    Blicklé JF
    Rev Med Interne; 2003 Nov; 24(11):709-10. PubMed ID: 14604746
    [No Abstract]   [Full Text] [Related]  

  • 7. Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation.
    Abbink EJ; van der Wal PS; Sweep CG; Smits P; Tack CJ
    Diabetes Metab Res Rev; 2004; 20(6):466-71. PubMed ID: 15386823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Rapaglinide: Novonorm, an alternative in type 2 diabetes].
    Bouhanick B; Barbosa SS
    Presse Med; 2000 May 27-Jun 3; 29(19):1059-61. PubMed ID: 10874917
    [No Abstract]   [Full Text] [Related]  

  • 9. Insulin secretagogues.
    Kock M
    J Assoc Physicians India; 1997; Suppl 1():48. PubMed ID: 11235637
    [No Abstract]   [Full Text] [Related]  

  • 10. The importance of early insulin secretion and its impact on glycaemic regulation.
    Garber AJ
    Int J Obes Relat Metab Disord; 2000 Sep; 24 Suppl 3():S32-7. PubMed ID: 11063282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Repaglinide].
    Quast U
    Dtsch Med Wochenschr; 2001 May; 126(19):559-60. PubMed ID: 11402913
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes.
    de Luis DA; Aller R; Cuellar L; Terroba C; Ovalle H; Izaola O; Romero E
    Diabetes Care; 2001 Oct; 24(10):1844-5. PubMed ID: 11574456
    [No Abstract]   [Full Text] [Related]  

  • 13. Repaglinide: a novel oral antidiabetic agent.
    Nattrass M
    Hosp Med; 2000 Feb; 61(2):112-5. PubMed ID: 10748789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Insulin secretion and repaglinide].
    Owens D
    Diabetes Metab; 1999 Dec; 25 Suppl 7():17-9. PubMed ID: 10746006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early-phase prandial insulin secretion: its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide.
    Owens DR; Cozma LS; Luzio SD
    Diabetes Nutr Metab; 2002 Dec; 15(6 Suppl):19-27. PubMed ID: 12702004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mechanisms of action of repaglinide at a cellular level].
    Thomsen MK
    Diabetes Metab; 1999 Dec; 25 Suppl 7():11-3. PubMed ID: 10746004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Repaglinide in combination therapy in type 2 diabetes].
    Moses R
    Diabetes Metab; 1999 Dec; 25 Suppl 7():26-7. PubMed ID: 10746009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in.
    Zhang H; Bu P; Xie YH; Luo J; Lei MX; Mo ZH; Liao EY
    Chin Med J (Engl); 2011 Jan; 124(2):172-6. PubMed ID: 21362360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide.
    Wu CZ; Pei D; Hsieh AT; Wang K; Lin JD; Lee LH; Chu YM; Hsiao FC; Pei C; Hsia TL
    Arch Pharm Res; 2010 Mar; 33(3):411-6. PubMed ID: 20361306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control.
    Chisalita SI; Lindström T; Eson Jennersjö P; Paulsson JF; Westermark GT; Olsson AG; Arnqvist HJ
    Acta Diabetol; 2009 Mar; 46(1):35-42. PubMed ID: 18777156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.